<DOC>
	<DOCNO>NCT01911741</DOCNO>
	<brief_summary>A study evaluate bioavailability ( BA ) single oral dose MDV3100 ( enzalutamide ) formulate solid spray dry tablet compare oral liquid-filled capsule , safety tolerability oral formulation . Subjects admit clinic day 1 5 , follow outpatient assessment Day 50 . They return clinic end study visit ( ESV ) 7-10 day last pharmacokinetic ( PK ) sample early withdrawal .</brief_summary>
	<brief_title>A Study Compare Capsule Tablet Forms MDV3100 ( Enzalutamide ) After Administration Single Set Dose Under Fasted Conditions Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>The subject body mass index ( BMI ) range 18.5 29.9 kg/m2 , inclusive . The subject weigh least 50 kg ( screen ) . Male subject female spouse/partner childbearing potential must use highly effective contraception consist two form birth control ( one must barrier method ) start screen continue throughout study period 3 month final study drug administration . Male subject must donate sperm start screen throughout study period least 3 month final study drug administration . Known suspect hypersensitivity enzalutamide , component formulation use . Confirmed CYP2C8 poor metabolizer status base genotyping analysis . Any history seizure include febrile seizure childhood , loss consciousness , transient ischemic attack , condition may predispose seizure . The subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior first clinic check . Use grapefruit marmalade week prior admission Clinical Unit , report subject . Any significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Relative bioavailability MDV3100</keyword>
	<keyword>Immediate release oral formulation</keyword>
	<keyword>Xtandi</keyword>
</DOC>